Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanO2TM in newly-diagnosed Glioblastoma Multiforme
NCT03862430Phase 2Active, not recruiting
- Sponsor
- NuvOx Therapeutics
- Start
- Mar 2023
- Primary completion
- Jun 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of perflenapent in glioblastoma multiforme (GBM) (2 arms), sponsored by NuvOx Therapeutics. Primary endpoint: Progression-Free Survival at 22 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
perflenapent
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03862430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862430.